[Skip to Content]
Sign In
Individual Sign In
Create an Account
Institutional Sign In
OpenAthens Shibboleth
[Skip to Content Landing]

June 2017 - July 1959

Decade

Year

Issue

July 2017, Vol 74, No. 7, Pages 661-764

In This Issue of JAMA Psychiatry

In This Issue

Abstract Full Text
free access
JAMA Psychiatry. 2017;74(7):661. doi:10.1001/jamapsychiatry.2016.2526
Viewpoint

Precision Psychiatry Meets Network MedicineNetwork Psychiatry

Abstract Full Text
JAMA Psychiatry. 2017;74(7):665-666. doi:10.1001/jamapsychiatry.2017.0580

This Viewpoint promotes network medicine as an approach that will place psychiatric diseases within broader disease networks and assist the stratification of subtypes of clinical conditions.

Extending the Benefits of Indicated Prevention to Improve Outcomes of First-Episode Psychosis

Abstract Full Text
JAMA Psychiatry. 2017;74(7):667-668. doi:10.1001/jamapsychiatry.2017.1009

This Viewpoint discusses the benefits and limitations of clinical high risk for psychosis services and suggests strategies for improvement.

Editorial

Suicide Risk After Psychiatric Hospital Discharge

Abstract Full Text
JAMA Psychiatry. 2017;74(7):669-670. doi:10.1001/jamapsychiatry.2017.1043

Understanding the Association Between Personality and Severe Mental Illness

Abstract Full Text
JAMA Psychiatry. 2017;74(7):671-672. doi:10.1001/jamapsychiatry.2017.0630

Late-Life Depression and the Prodromes of Dementia

Abstract Full Text
JAMA Psychiatry. 2017;74(7):673-674. doi:10.1001/jamapsychiatry.2017.0658
Original Investigation

Meta-analysis

Efficacy of 42 Pharmacologic Cotreatment Strategies Added to Antipsychotic Monotherapy in SchizophreniaSystematic Overview and Quality Appraisal of the Meta-analytic Evidence

Abstract Full Text
JAMA Psychiatry. 2017;74(7):675-684. doi:10.1001/jamapsychiatry.2017.0624

This meta-analysis compares the multiple pharmacologic combination strategies that have been studied for suboptimal treatment responses in schizophrenia to facilitate decision making.

Real-World Effectiveness of Antipsychotic Treatments in a Nationwide Cohort of 29 823 Patients With Schizophrenia

Abstract Full Text
JAMA Psychiatry. 2017;74(7):686-693. doi:10.1001/jamapsychiatry.2017.1322

This database study uses a nationwide cohort to examine the comparative real-world effectiveness of antipsychotic treatments for patients with schizophrenia.

Meta-analysis

Suicide Rates After Discharge From Psychiatric FacilitiesA Systematic Review and Meta-analysis

Abstract Full Text
JAMA Psychiatry. 2017;74(7):694-702. doi:10.1001/jamapsychiatry.2017.1044

This meta-analysis quantifies the rates of suicide after discharge from psychiatric facilities and examines what moderates those rates.

Association of Late Adolescent Personality With Risk for Subsequent Serious Mental Illness Among Men in a Swedish Nationwide Cohort Study

Abstract Full Text
JAMA Psychiatry. 2017;74(7):703-711. doi:10.1001/jamapsychiatry.2017.0583

This longitudinal nationwide cohort study determines the association of the adolescent personality domains of social maturity, mental energy, and emotional stability with later diagnosis of serious mental illness among Swedish men.

Trajectories of Depressive Symptoms Before Diagnosis of DementiaA 28-Year Follow-up Study

Abstract Full Text
JAMA Psychiatry. 2017;74(7):712-718. doi:10.1001/jamapsychiatry.2017.0660

This cohort study characterizes the trajectory of depressive symptoms over 28 years prior to dementia diagnosis to determine whether depressive symptoms carry risk for dementia.

Effect of Liraglutide Treatment on Prediabetes and Overweight or Obesity in Clozapine- or Olanzapine-Treated Patients With Schizophrenia Spectrum DisorderA Randomized Clinical Trial

Abstract Full Text
has active quiz
JAMA Psychiatry. 2017;74(7):719-728. doi:10.1001/jamapsychiatry.2017.1220

This randomized clinical trial investigates the effect of liraglutide added to clozapine or olanzapine treatment of schizophrenia spectrum disorders in patients with prediabetes who are overweight or obese.

Meta-analysis

Association of Microvascular Dysfunction With Late-Life DepressionA Systematic Review and Meta-analysis

Abstract Full Text
JAMA Psychiatry. 2017;74(7):729-739. doi:10.1001/jamapsychiatry.2017.0984

This systematic review and meta-analysis examines the associations of the peripheral and cerebral forms of microvascular dysfunction with late-life depression.

Association of Streptococcal Throat Infection With Mental DisordersTesting Key Aspects of the PANDAS Hypothesis in a Nationwide Study

Abstract Full Text
JAMA Psychiatry. 2017;74(7):740-746. doi:10.1001/jamapsychiatry.2017.0995

This population-based cohort study investigates the risk of mental disorders, specifically obsessive-compulsive disorder and tic disorders, after a streptococcal throat infection.

Simultaneous Antidepressant and Benzodiazepine New Use and Subsequent Long-term Benzodiazepine Use in Adults With Depression, United States, 2001-2014

Abstract Full Text
JAMA Psychiatry. 2017;74(7):747-755. doi:10.1001/jamapsychiatry.2017.1273

This study examines simultaneous new benzodiazepine and antidepressant use among adults with depression, antidepressant treatment length by simultaneous new use status, subsequent long-term benzodiazepine use in those taking both an antidepressant and a benzodiazepine, and determinants of simultaneous new use and long-term benzodiazepine use.

Invited Commentary

A Meta View on Meta-analyses

Abstract Full Text
JAMA Psychiatry. 2017;74(7):684-685. doi:10.1001/jamapsychiatry.2017.1167
Comment & Response

Lessons to Be Learned From 22q11.2 Syndromes

Abstract Full Text
JAMA Psychiatry. 2017;74(7):757. doi:10.1001/jamapsychiatry.2017.0831

Lessons to be Learned From 22q2.11 Syndromes—Reply

Abstract Full Text
JAMA Psychiatry. 2017;74(7):757-758. doi:10.1001/jamapsychiatry.2017.0837

Defining Treatment-Resistant Depression

Abstract Full Text
JAMA Psychiatry. 2017;74(7):758-759. doi:10.1001/jamapsychiatry.2017.0967

Defining Treatment-Resistant Depression—Reply

Abstract Full Text
JAMA Psychiatry. 2017;74(7):759. doi:10.1001/jamapsychiatry.2017.0970

Are There Differences in Disruptions of Reward Processing Between Substance Use Disorder and Gambling Disorder?

Abstract Full Text
JAMA Psychiatry. 2017;74(7):759-760. doi:10.1001/jamapsychiatry.2017.1051

Are There Differences in Disruptions of Reward Processing Between Substance Use Disorder and Gambling Disorder?—Reply

Abstract Full Text
JAMA Psychiatry. 2017;74(7):760-761. doi:10.1001/jamapsychiatry.2017.1054

First-Episode Schizophrenia and Diabetes Risk

Abstract Full Text
JAMA Psychiatry. 2017;74(7):761. doi:10.1001/jamapsychiatry.2017.0760

First-Episode Schizophrenia and Diabetes Risk

Abstract Full Text
JAMA Psychiatry. 2017;74(7):761-762. doi:10.1001/jamapsychiatry.2017.0762

First-Episode Schizophrenia and Diabetes Risk

Abstract Full Text
JAMA Psychiatry. 2017;74(7):762-763. doi:10.1001/jamapsychiatry.2017.0905

First-Episode Schizophrenia and Diabetes Risk—Reply

Abstract Full Text
JAMA Psychiatry. 2017;74(7):763. doi:10.1001/jamapsychiatry.2017.0765
Correction

Omission in Funding/Support Section

Abstract Full Text
free access
JAMA Psychiatry. 2017;74(7):764. doi:10.1001/jamapsychiatry.2017.1108

Incorrect SD Values in Table 1

Abstract Full Text
free access
JAMA Psychiatry. 2017;74(7):764. doi:10.1001/jamapsychiatry.2017.1446

Incomplete Author Name in Byline

Abstract Full Text
free access
JAMA Psychiatry. 2017;74(7):764. doi:10.1001/jamapsychiatry.2017.1587
JAMA Psychiatry Masthead

JAMA Psychiatry

Abstract Full Text
free access
JAMA Psychiatry. 2017;74(7):663. doi:10.1001/jamapsychiatry.2016.2527
×